[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
We have retrospectively been collecting data on adverse reactions to FOLFIRI chemotherapy in our hospital from September 2005 to August 2006, by electronic medical records. The retrospective study was of 67 patients who received FOLFIRI for advanced colorectal cancer. Survey results showed high incidences of vomiting(58.2%), anorexia(91.4%), constipation (47.8%), diarrhea (61.2%) and alopecia(71.6%). The first cycle using FOLFIRI therapy, vomiting (20.9%), anorexia(53.7%), constipation ( 14.9%), and diarrhea (23.9%)were observed. We sought to minimize inter-individual differences in pharmaceutical care and drug consultation by clinical pharmacists and to ensure the accurate understanding of patients. We are sure that this kind of activity will help us to provide better pharmaceutical care for patients.
Kamisugi
Kayoko
K
Dept. of Pharmacy, Cancer Institute Hospital.
Matsusaka
Satoshi
S
Imada
Hiroshi
H
Shoji
Daigo
D
Nakamoto
Eri
E
Yokokawa
Takashi
T
Kawakami
Kazuyoshi
K
Hirata
Yoshimi
Y
Nawano
Kazumi
K
Ogawa
Megumi
M
Shinozaki
Eiji
E
Suenaga
Mitsukuni
M
Mizunuma
Nobuyuki
N
Hatake
Kiyohiko
K
Hama
Toshihiro
T
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006306:Health Surveys; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010174:Pamphlets
D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin